Citius Oncology Reports Preliminary Fiscal Q4 2026 Operational Results
Citius Oncology announced a 120% increase in wholesaler shipments of its LYMPHIR immunotherapy for the fiscal fourth quarter of 2026.
Stocks · News reference
Citius Oncology Reports Preliminary Q4 FY2026 LYMPHIR Wholesaler Unit Sales More Than Doubling 120% To 792 Units, With 950 Institutional Vial Orders And 54 Institutions Ordering The CTCL Treatment
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Citius Oncology Reports Fiscal Q4 2026 Preliminary LYMPHIR Sales Data
Citius Pharmaceuticals' majority-owned subsidiary, Citius Oncology, reported preliminary, unaudited fiscal fourth-quarter 2026 sales data for its FDA-approved immunotherapy, LYMPHIR.
8-K filing — CITIUS ONCOLOGY, INC. (CTOR)
Filed: 2026-10-26 AccNo: 0001213900-26-112477 Size: 247 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
8-K filing — Citius Pharmaceuticals, Inc. (CTXR)
Filed: 2026-10-26 AccNo: 0001213900-26-112478 Size: 232 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers INVO Fertility (NASDAQ:IVF) shares moved upwards by 108.9% to $2.03 during Monday's regular session. The market value of their outstanding shares is at $1.7 million. As per the press release, Q2 earnings
Citius Oncology shares are trading lower after the company reported worse-than-expected Q3 sales results.